Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Option Exercise and Share Sales

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 5, 2025, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 5,000 shares of common stock at a price of $21.41 per share.
• On the same day, Eydelman sold a total of 5,000 shares of common stock in multiple transactions at weighted-average prices ranging from $87.767 to $91.708.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2024.
• Following these transactions, Eydelman directly owns 28,222 shares of Vaxcyte common stock and holds options for 149,497 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine executive stock transactions under a pre-established plan. There's no indication of unusual activity or cause for alarm.

Positives

• The Rule 10b5-1 trading plan suggests a pre-arranged strategy for selling shares, potentially mitigating concerns about insider trading.

Negatives

• The sale of shares by a company executive could be perceived negatively by some investors, although it's part of a pre-planned strategy.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.

Future Outlook

The document does not contain specific forward-looking statements beyond the ongoing operation of the Rule 10b5-1 trading plan.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations. This filing provides transparency into the transactions of a key executive at Vaxcyte.

Comparison to Industry Standards

• Executive compensation packages often include stock options and equity grants to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are widely used by corporate insiders to manage their stock sales in a compliant manner, similar to practices at companies like Pfizer, Moderna, and BioNTech.
• The reported weighted average sale prices are within the typical range observed for similar transactions in the biotechnology sector.

Stakeholder Impact

• Shareholders may monitor executive stock transactions for insights into management's perspective on the company's value.
• Employees may be interested in the stock-related activities of company executives.

Key Dates